Hepatitis C
Updated Boceprevir (Victrelis) Label Adds Data on Prior Null Responders
- Details
- Category: HCV Treatment
- Published on Friday, 15 February 2013 00:00
The U.S. Food and Drug Administration (FDA) announced this week that the product label information for the hepatitis C virus (HCV) protease inhibitor boceprevir (brand name Victrelis) has been updated to include data on treatment of prior null responders.
HCV Polymerase Inhibitor Mericitabine Boosts Interferon/Ribavirin Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 February 2013 00:00
A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.
Tattoos Are Associated with Hepatitis C Virus Infection in the Absence of Other Risk Factors
- Details
- Category: HCV Prevention
- Published on Tuesday, 29 January 2013 00:00
Individuals with chronic hepatitis C virus (HCV) infection in New York City were about 5 times more likely to have a tattoo than people without HCV, even after traditional risk factors such as injection drug use were taken into account, researchers reported in the January 12, 2013, advance online edition of Hepatology.
Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.
Boceprevir and Telaprevir Improve Hepatitis C Treatment, Literature Reviews Find
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 January 2013 00:00
Triple therapy with a direct-acting antiviral drug was more effective than pegylated interferon and ribavirin alone for people with chronic hepatitis C, but there is not yet enough data to determine many differences between boceprevir (Victrelis) and telaprevir (Incivek), or to see effects on long-term clinical outcomes, according to 2 recent medical literature reviews.
Sofosbuvir Combos Match or Beat Standard Hepatitis C Therapy For All Genotypes
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
The experimental hepatitis C polymerase inhibitor sofosbuvir in an all-oral regimen with ribavirin worked as well as interferon-based therapy for previously untreated people with HCV genotypes 2 or 3, while adding sofosbuvir to pegylated interferon/ribavirin increased cure rates for those with more difficult-to-treat genotypes, Gilead Sciences announced this week.
Boehringer Ingelheim Starts Phase 3 Trial of Interferon-free Faldaprevir + BI 207127
- Details
- Category: HCV Treatment
- Published on Thursday, 24 January 2013 00:00
The Phase 3 HCVerso trial, testing an all-oral regimen containing Boehringer Ingelheim's HCV protease inhibitor faldaprevir (formerly BI 201335), polymerase inhibitor BI 207127, and ribavirin has begun enrollment, the company announced last week.
TAG Releases Updated Guide to Hepatitis C Clinical Trials
- Details
- Category: HCV Treatment
- Published on Friday, 01 February 2013 00:00
The Treatment Action Group (TAG) has produced an updated edition of its guide for people considering participating in clinical trials of new therapies for hepatitis C. Written by Matt Sharp and Tracy Swan, the revised Guide to Clinical Trials for People with Hepatitis C provides an overview of the drug development process, along with information about specific types of HCV treatment.
Water and Filters Used for Drug Injection May Transmit Hepatitis C Virus
- Details
- Category: HCV Prevention
- Published on Friday, 11 January 2013 00:00
Water, containers, and material used to mix and filter heroin -- not just syringes -- can harbor hepatitis C virus (HCV) and contribute to transmission among injection drug users, according to a study published in the November 5, 2012, advance edition of the Journal of Infectious Diseases.
More Articles...
- Gilead Provides More Sofosbuvir Data, Plans for Further Hepatitis C Studies
- Achillion Reports Promising Data on All-oral Hepatitis C Regimen with ACH-3102
- HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- NEJM: Sofosbuvir, ABT-450, ABT-333 Look Good in Interferon-free Hepatitis C Regimens
- Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks
Web Design and Development by